Cardiac Markers
2nd Edition
Published on 12. June 2003
Book
Hardback
XVII, 467 pages
978-1-58829-036-6 (ISBN)
Description
In this greatly enlarged and thoroughly updated edition of his much praised Cardiac Markers, Alan Wu and his contributors focus on the use of markers in the practice of cardiology and-for the first time-on the use of natriuretic peptides for congestive heart failure. Here, leading international authorities in clinical chemistry and laboratory medicine, cardiology, emergency medicine, and the in vitro diagnostics industry describe the state-of-the-art uses of cardiac markers when treating coronary artery disease, and discuss in detail how they may be optimally used in a clinical setting. Comprehensive and cutting-edge, Cardiac Markers, Second Edition offers physicians a complete guide to the use of cardiac markers in clinical practice and clinical laboratorians a close-up view of the new markers now becoming standard.
Reviews / Votes
"addresses the need in a variety of disciplines for an understanding of the evolving role of cardiac markers, particularly in relation to the diagnosis and treatment of acute coronary syndromes. The book provides a concise and informative summary of a rapidly developing field and will be a useful addition to the book-shelves of clinical pathologists, emergency physicians, and cardiologists." -New England Journal of Medicine"...a valuable addition to the compendium of laboratory medicine literature on diagnostic tests and their appropriate clinical application...highly recommended for any individual interested in the state-of-the-art of appropriate laboratory assessment of the acute coronary syndrome patient." -Doody's Health Sciences Book Review Journal
"This comprehensive book not only offers physicians a complete guide to the use of cardiac markers in clinical practice, but also provides clinical laboratories with detailed information on the new markers which are now becoming standard." - Clinical Laboratory International
"...highly recommended as a reference resource for cardiologists, internists, emergency medicine physicians, and laboratory medicine physicians who have specific questions regarding the many clinically relevant cardiac markers...will save the physician considerable time and effort in answering a specific question that he or she may have within this rapidly evolving field." - Texas Heart Institute Journal
From reviews of the first edition...
"...provides a concise and informative summary of a rapidly developing field and will be a useful addition to the bookshelves of clinical pathologists, emergency physicians, and cardiologists." -New England Journal of Medicine
"...a valuable addition to the compendium of laboratory medicine literature on diagnostic tests and their appropriate clinical application...highly recommendedfor any individual interested in the state-of-the-art of appropriate laboratory assessment of the acute coronary syndrome patient." -Doody's Health Sciences Book Review Journal
More details
Series
Edition
2nd ed. 2003
Language
English
Place of publication
Totowa
United States
Target group
Professional and scholarly
Professional/practitioner
Edition type
Revised edition
Illustrations
XVII, 467 p.
Dimensions
Height: 260 mm
Width: 183 mm
Thickness: 31 mm
Weight
1107 gr
ISBN-13
978-1-58829-036-6 (9781588290366)
DOI
10.1007/978-1-59259-385-9
Schweitzer Classification
Other editions
Additional editions
Alan H. B. Wu
Cardiac Markers
Book
11/2010
2nd Edition
Humana Press Inc.
€213.99
Shipment within 15-20 days
Content
I. Cardiac Markers in Clinical Practice.- 1 Early Detection of Myocardial Necrosis in the Emergency Setting and Utility of Serum Biomarkers in Chest Pain Unit Protocols.- 2 Management of Acute Coronary Syndromes.- 3 Evolution of Cardiac Markers in Clinical Trials.- 4 Assessing Reperfusion and Prognostic Infarct Sizing with Biochemical Markers: Practice and Promise.- 5 The Use of Cardiac Biomarkers to Detect Myocardial Damage Induced by Chemotherapeutic Agents.- 6 The Use of Biomarkers to Provide Diagnostic and Prognostic Information Following Cardiac Surgery.- II. Clinical Use for Cardiac Troponins.- 7 Cardiac Troponins: Exploiting the Diagnostic Potential of Disease-Induced Protein Modifications.- 8 Cardiac Troponin Testing in Renal Failure and Skeletal Muscle Disease Patients.- 9 Cardiac-Specific Troponins Beyond Ischemic Heart Disease.- III. Analytical Issues for Cardiac Markers.- 10 Antibody Selection Strategies in Cardiac Troponin Assays.- 11 Interferences in Immunoassays for Cardiac Troponin.- 12 Cardiac Marker Measurement by Point-of-Care Testing.- 13 Standardization of Cardiac Markers.- 14 Analytical Issues and the Evolution of Cutoff Concentrations for Cardiac Markers.- IV. Early Cardiac Markers of Myocardial Ischemia and Risk Stratification.- 15 Rationale for the Early Clinical Application of Markers of Ischemia in Patients with Suspected Acute Coronary Syndromes.- 16 Ischemia-Modified Albumin, Free Fatty Acids, Whole Blood Choline, B-Type Natriuretic Peptide, Glycogen Phosphorylase BB, and Cardiac Troponin.- 17 C-Reactive Protein for Primary Risk Assessment.- 18 Prognostic Role of Plasma High-Sensitivity C-Reactive Protein Levels in Acute Coronary Syndromes.- 19 Preanalytic and Analytic Sources of Variations in C-Reactive Protein Measurement.- 20 Fatty Acid Binding Protein as an Early Plasma Marker of Myocardial Ischemia and Risk Stratification.- 21 Oxidized Low-Density Lipoprotein and Malondialdehyde-Modified Low-Density Lipoprotein in Patients with Coronary Artery Disease.- V. Cardiac Markers of Congestive Heart Failure.- 22 Pathophysiology of Heart Failure.- 23 B-Type Natriuretic Peptide: Biochemistry and Measurement.- 24 B-Type Natriuretic Peptide in the Diagnoses and Management of Congestive Heart Failure.- 25 Monitoring Efficacy of Treatment with Brain Natriuretic Peptide.- 26 N-Terminal Pro-B-Type Natriuretic Peptide.- VI. Role of Infectious Diseases and Genetics in Heart Disease.- 27 Infectious Diseases in the Etiology of Atherosclerosis and Acute Coronary Syndromes: Focus on Chlamydia pneumoniae.- 28 Polymorphisms Related to Acute Coronary Syndromes and Heart Failure: Potential Targets for Pharmacogenomics.